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Objectives The purpose of the study was to systematically evaluate the significance of platelet reactivity on clopidogrel
treatment on adverse cardiovascular events using a collaborative meta-analysis using patient-level data for the
VerifyNow P2Y12 assay (Accumetrics, San Diego, California).
Background Clinical evidence has been controversial regarding the influence of clopidogrel on treatment platelet reactivity
and ischemic outcomes.
Methods MEDLINE, Scopus, and the Cochrane library databases were searched through January 2010. A database con-
taining individual patient-level time-to-event data was generated from identified studies. The primary outcome of
interest was a composite of death, myocardial infarction (MI), or stent thrombosis. Secondary outcomes in-
cluded the incidence of: 1) death; 2) MI; and 3) stent thrombosis.
Results A total of 6 studies with 3,059 patients was included. In each study, clopidogrel responsiveness was assessed using
the same point-of-care assay after percutaneous coronary intervention. The primary endpoint occurred more fre-
quently in higher quartiles of P2Y12 reaction unit (PRU) values: quartile I, 5.8%; quartile II, 6.9%; quartile III, 10.9%;
quartile IV, 15.8% (p  0.001). Taking quartile I as referent, the hazard ratios (HRs) for the primary endpoint were as
follows: quartile II, HR: 1.13 (95% confidence interval [CI]: 0.72 to 1.78; p  0.60); quartile III, HR: 1.82 (95% CI: 1.20
to 2.75; p  0.005); quartile IV, HR: 2.62 (95% CI: 1.78 to 3.87; p  0.001). On a continuous scale, every 10-U in-
crease in PRU was associated with a significantly higher rate of the primary endpoint (HR: 1.04; 95% CI: 1.03 to 1.06;
p  0.0001). According to receiver-operating characteristic curve analysis, a PRU value of 230 appeared to best pre-
dict death, MI, or stent thrombosis (p  0.001). A PRU value 230 was associated with a higher rate of the compos-
ite primary endpoint (HR: 2.10; 95% CI: 1.62 to 2.73; p  0.0001), as well as the individual endpoints of death (HR:
1.66; 95% CI: 1.04 to 2.68; p  0.04), MI (HR: 2.04; 95% CI: 1.51 to 2.76; p  0.001), and stent thrombosis (HR:
3.11; 95% CI: 1.50 to 6.46; p  0.002).
Conclusions In this collaborative meta-analysis, the level of on-treatment platelet reactivity according to the P2Y12 assay is associ-
ated with long-term cardiovascular events after percutaneous coronary intervention, including death, MI, and stent
thrombosis. (J Am Coll Cardiol 2011;58:1945–54) © 2011 by the American College of Cardiology Foundation
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Platelet Reactivity and Clinical Outcomes November 1, 2011:1945–54Dual antiplatelet therapy with
aspirin and a thienopyridine is
essential after percutaneous cor-
onary intervention (PCI) with
stent implantation (1,2). How-
ever, significant interindividual
variability exists in clopidogrel-
induced inhibition of platelet
activation through the P2Y12
pathway. Several methods for as-
sessment of on-clopidogrel treat-
ment platelet reactivity have been
developed (3). Although high
on-treatment platelet reactivity
has been associated with adverse
cardiac events after PCI, the
studies have had limited sample
sizes, involved only single centers, and assessed only com-
posite clinical endpoints. Therefore, we sought to investi-
gate the relation of high on-treatment platelet reactivity
with both composite and individual ischemic outcomes after
PCI using a collaborative meta-analysis of patient-level
data, and to derive a clinically meaningful cut-off platelet
reactivity value to identify patients at risk of future ischemic
events.
See page 1955
Methods
Literature search. We identified published studies assess-
ing platelet reactivity using uniform methodology with a
commercially available, point-of-care, cartridge-based assay
(VerifyNow P2Y12 assay, Accumetrics, San Diego, Califor-
nia). The search criteria used were key words, databases, and
conference proceedings. Key words included the following
in various combinations: platelet reactivity, clopidogrel, and
VerifyNow. The databases searched included MEDLINE
(1966 through January 2010), Scopus (1980 through Janu-
ary 2010), and the Cochrane Library (1993 through January
2010). We also searched conference proceedings of the
American College of Cardiology, American Heart Associ-
ation, Transcatheter Cardiovascular Therapeutics, and Eu-
ropean Society of Cardiology for “late breaking” presenta-
tions from 2005 to 2009. The references of review articles,
meta-analysis, and evidence based-guidelines were reviewed
by 2 authors (S.S.B. and G.D.) (1,2,4). We did not use
language restriction in the search.
Study selection. To be included in this analyses studies
needed to meet the following criteria: 1) use the VerifyNow
and Bristol-Myers Squibb (modest level); has provided consultancy services for
AstraZeneca (modest level); has received a fellowship program grant from Accumet-
rics; and has received speaker honoraria from Cordis/J&J and AstraZeneca. All other
authors have reported that they have no relationships relevant to this paper to disclose.
Abbreviations
and Acronyms
AUC  area under the
curve
CI  confidence interval
HR  hazard ratio
IDI  integrated
discrimination improvement
MI  myocardial infarction
NRI  net reclassification
improvement
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction
unit(s)Manuscript received February 20, 2011; revised manuscript received May 6, 2011,
accepted June 7, 2011.P2Y12 test to assess platelet reactivity; 2) report the timing
of assay performance in relation to PCI and clopidogrel
loading; 3) report outcomes for death and myocardial
infarction (MI); and 4) report at least 30-day follow-up.
Articles meeting the inclusion criteria were selected for
further analysis. The investigators of the identified studies
were contacted, and each agreed to provide patient-level
data.
Study outcomes and data collection. The primary end-
point of this study was the composite of death, MI, or stent
thrombosis from the index PCI. The endpoints were
defined according to the individual study protocols. Second-
ary endpoints included each 1 of the above components of
the primary endpoint.
An electronic form containing the data elements to be
completed for the patient-level meta-analysis was sent to all
the principal investigators of the identified studies. Individ-
ual patient-level data were provided for all 6 trials identified.
The data requested for each enrolled patient included the
date of the procedure, diabetes mellitus status, event status
(including death, MI, or stent thrombosis), age, sex, hyper-
tension status, dyslipidemia, type of clinical presentation,
stent type, and date of last follow-up. Any queries were
resolved, and the respective study investigators verified the
final database entries.
PCI and antiplatelet management. All interventions were
performed according to local standards. The type of stent
implanted was left to the discretion of the operator in all
studies. All patients received 1 clopidogrel loading dose of
300 to 600 mg followed by a daily dose of 75 mg. Aspirin,
100 to 325 mg orally, was administered post-procedure.
Anticoagulation therapy with either heparin or bivalirudin
was at the discretion of the operator.
Platelet reactivity assessment. The time of blood with-
drawal for P2Y12 testing was at the time of PCI in patients
re-treated with clopidogrel or at least 1 day after the
lopidogrel loading dose. A uniform testing method for
lopidogrel responsiveness was selected to eliminate the
ariability in assessment of platelet reactivity by different
ematologic assays. Platelet reactivity testing to clopidogrel
herapy was performed using the VerifyNow P2Y12 assay
Accumetrics). This method has been approved for human
se by the U.S. Food and Drug Administration. This assay
s a turbidimetry-based optical detection device that mea-
ures platelet-induced aggregation in a system containing
brinogen-coated beads. The P2Y12 assay contains 20 M
ADP, as the platelet agonist, and 22 nmol prostaglandin
E1, to reduce the contribution of ADP binding to P2Y12
receptors. The instrument measures platelet-induced aggre-
gation of the beads as an increase in light and expresses the
results as P2Y12 reaction units (PRU).
Statistical methods. Categorical variables were compared
by the chi-square test or Fisher exact test. Continuous
variables are reported as mean  SD and were compared by
unpaired t tests. For variables that were not normally
distributed (e.g., PRU quartiles), the Wilcoxon test was
s
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November 1, 2011:1945–54 Platelet Reactivity and Clinical Outcomesused for comparing 2 groups, and the Kruskal-Wallis for
2 groups (e.g., PRU values between studies).
Time-to-event data are reported and displayed using the
Kaplan-Meier method, with comparisons between groups
performed using the log-rank test. Cumulative survival
curves by PRU quartiles were constructed by the Kaplan-
Meier method. Quartiles II, III, and IV were compared to
quartile I with the log-rank test. In the survival analyses,
adjustments for multiple comparisons were performed by
applying the Sida´k correction to the raw p values (5).
Analyses were truncated at 2 years of follow-up because of
the small number of patients with available data thereafter.
Cox proportional hazards models were also generated for
the primary efficacy and safety outcomes. The proportion-
ality assumption was tested using log(log) plots and
Schöenfeld residuals; the assumption was satisfied by both
tests.
A landmark analysis was used to determine if there were
long-term differences in the primary endpoint between
groups with normal versus high on-treatment platelet reac-
tivity after excluding periprocedural events. In this analysis,
all patients with events within the first 3 days after PCI were
excluded.
Logistic regression was used to generate a receiver-
operating characteristic curve for the PRU values and the
primary endpoint. The area under the curve (AUC) or
c-statistic was determined from this model, as was the
optimal cutpoint; the latter was determined by the PRU
value that maximized the following relationship: sensitivity 
(1  specificity). Model goodness of fit was tested and
atisfied by the Hosmer-Lemeshow goodness-of-fit test.
he robustness of the PRU threshold value was also
ssessed in sensitivity analyses. The cohort was randomly
ivided into a derivation and validation dataset, with 50% of
he sample distributed to each dataset. In the derivation
ataset, bootstrap estimates (sampling with replacement) of
he PRU threshold were calculated for 100 iterations,
ielding the best average cutoff and 95% confidence interval
CI). For estimates of standard errors and normal approx-
mation CI, 100 bootstrap replications are generally ade-
uate. Next, Kaplan-Meier failure estimates and hazard
atios (HR) were calculated using the PRU threshold in the
erivation and validation cohorts.
The increased discriminative value of platelet function
esting was further examined using net reclassification
mprovement (NRI) and integrated discrimination im-
rovement (IDI) (6). The NRI was calculated by assessing
he net improvement in risk classification. This method
equires that there exist a priori risk categories. In the
bsence of well-established risk categories, we used 0% to 4%,
% to 10%, and 10% for the risk of the composite end-
oint of death, MI, or stent thrombosis (Online Appendix).
Subgroups for further analyses were specified a priori and
ncluded age, sex, diabetes status, stent type, and acute
oronary syndrome presentation. The Cochrane Q statisticnd the I2 statistic were used to assess the heterogeneity
across trials. A Cochrane Q statistic with a p value0.1 was
considered significant. The I2 statistic was used to measure
he consistency among trials with values of 25%, 50%, and
5% showing, respectively, low, moderate, and high heter-
geneity. A funnel plot was used to assess for the presence
f publication and other reporting biases by plotting the
tandard error against the log risk ratio. Using Egger’s
egression method, we examined the association between
he study size and estimated treatment (7).
The p value threshold for statistical significance was set at
.05. Analyses were conducted by S.S.B in Stata 10.1 (Stata
orp., College Station, Texas) and SAS version 9.2 (SAS
nstitute, Cary, North Carolina). The study was performed
n accordance to the recommendations set forth by the
UOROM (Quality of Reporting of Meta-Analysis) and
he MOOSE (Meta-Analysis of Observational Studies in
pidemiology) work groups (8,9).
esults
ight studies were identified, and 6 were included in the
ooled analysis. Follow-up in 1 study was limited to
n-hospital events, and therefore it did not meet inclusion
riteria (10). We also excluded 1 study where testing was
erformed in an unspecified time frame shortly after oral
lopidogrel loading dose was administered (11). The au-
hors of all 6 studies that met inclusion criteria provided
atient-level data for analysis (12–17). Data on death and
I were available from all 6 studies; stent thrombosis data
ere available from 5 of the studies. Data were collected
rospectively in each of the studies included. Endpoints
ere adjudicated by an independent endpoints committee in
of the studies (12,17). When studies included treatment
rms or groups treated with antiplatelet therapies other than
lopidogrel and aspirin, we only included patients receiving
he combination of clopidogrel and aspirin (13,14).
Study characteristics are shown in Table 1. The age of the
ohort was 66  10 years, 68% were male, 24% were
iabetic, 74% had hypertension, 64% had dyslipidemia, and
0% were smokers. The time of blood withdrawal for P2Y12
testing was at the time of PCI in patients pre-treated with
clopidogrel or at least 1 day after the clopidogrel loading
dose. The distribution of PRU values by study and quartile
is shown in Figure 1. The mean platelet reactivity of the full
cohort was 196.5  84.5 PRU and the median was 200
RU (interquartile range [IQR]: 121 PRU). The median
alues were qualitatively comparable between studies, except
or the study by Campo et al. (13), which had the lowest
edian PRU value (p  0.001). Quartile I represents
atients with the lowest on-treatment platelet reactivity,
hereas quartile IV represents patients with the highest
n-treatment platelet reactivity. In the full study cohort, the
ean PRU values for quartiles I to IV were 84.5 37.3, 171 18.7, 229.7  16.7, and 301  32.9, respectively (p
†
ascular
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Platelet Reactivity and Clinical Outcomes November 1, 2011:1945–54 0.001). The median PRU values were 92 (IQR: 57), 172
(IQR: 33), 229 (IQR: 28), and 294 (IQR: 49), respectively
(p  0.001). The PRU range for quartiles I to IV were
138, 138 to 200, 201 to 258, and 258, respectively.
Heterogeneity and small study effects. Before performing
the pooled analysis, we assessed heterogeneity across studies.
Study CharacteristicsTable 1 Study Characteristics
Breet et al. (12) Marcucci et al. (15)
Study year 2010 2009
Sample size 1,069 683
Age, yrs 4 11 68 9
Women 267 (25.0) 172 (25.2)
Diabetes 199 (18.7) 178 (26.1)
Acute coronary syndrome 0 (0) 683 (100)
Drug-eluting stent use 675 (63.1) 121 (17.7)
Clopidogrel loading dose 300 mg if 24 h
before PCI, else
600 mg 4 h
before PCI
600 mg 30
Minimum duration of
clopidogrel therapy, months
12 12
Timing of platelet
responsiveness
At time of PCI 24 h post-PCI 24
Primary endpoint All-cause death, MI,
stent thrombosis,
ischemic stroke
Cardiovascular death, MI Ca
Duration of follow-up, months 12 12
Values are n, mean SD, or n (%) unless otherwise indicated. *Duration of clopidogrel was at least
1-month minimum in patients treated with bare-metal stents.
MI  myocardial infarction; PCI  percutaneous coronary intervention; TLR  target lesion rev
Figure 1 Distribution of PRU by Study and Quartile
Plot of the distribution of P2Y reaction units (PRU) by study and quartile. IQR 12There was no evidence for heterogeneity between studies by
either the Cochrane Q statistic (p  0.56) or the I2 statistic
(I2  0%). Also, visual inspection of the funnel plot did not
reveal asymmetry in the studies (Online Fig. 1). In support,
Egger’s regression test was not statistically significant for a
small study effect or publication bias (p  0.62).
t al. (14) Patti et al. (16) Price et al. (17) Campo et al. (13)
2010 2008 2008 2010
361 160 317 468
3 9 66 9 67 11 67 9
6 (26.9) 31 (19.4) 70 (22.1) 119 (25.4)
1 (30.8) 55 (34.4) 93 (29.3) 111 (23.7)
7 (38.0) 87 (54.4) 20 (6.3) 152 (32.5)
1 (100) 41 (26) 317 (100) 314 (67)
if 24 h
e PCI, else
g 4 h
e PCI
600 mg 600 mg 600 mg
6 12* 6 6†
post-PCI At time of PCI 12 h post-PCI and
clopidogrel load
At time of PCI
scular death,
chemic
, and TLR
Cardiovascular death,
MI, TVR
Cardiovascular death,
MI, stent
thrombosis
All-cause death, MI,
ischemic stroke
6 1 6 12
2months in patients presenting with acute coronary syndrome or treated with drug-eluting stents.
ization; TVR  target vessel revascularization.
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November 1, 2011:1945–54 Platelet Reactivity and Clinical OutcomesMain outcomes. The long-term clinical outcomes for the
primary composite endpoint of death, MI, or stent throm-
bosis are shown in Figure 2. Multiple pair-wise comparisons
were performed, taking quartile I as referent. All pair-wise
comparisons were adjusted for multiple testing as previously
described. The event rates were similar between quartiles I
and II (p  0.97). However, the event rates in quartiles III
nd IV were significantly greater compared to quartile I
p  0.02 and p  0.001, respectively). The HRs for the
rimary endpoint for quartiles II, III, and IV compared to
uartile I were 1.13 (95% CI: 0.72 to 1.78), 1.82 (95% CI:
.20 to 2.75), and 2.62 (95% CI: 1.77 to 3.87), respectively.
hen PRU values were analyzed on the continuous scale,
here remained a statistically significant association. There
as a 4% increase in the primary endpoint for every 10-unit
ncrease in PRU (HR: 1.04; 95% CI: 1.03 to 1.06; p 
.0001).
The rate of death was not significantly different across
RU quartiles, although the highest rate of death occurred
n quartile IV (Fig. 3A). The pair-wise comparisons, taking
uartile I as referent, were not significantly different for
uartile II (p  0.97), quartile III (p  0.92), and quartile
V (p  0.30). The HRs for mortality for quartiles II, III,
nd IV compared to quartile I were 0.84 (95% CI: 0.39 to
.81), 1.24 (95% CI: 0.62 to 2.50), and 1.67 (95% CI: 0.85
o 3.23), respectively.
The rate of MI differed significantly between quartiles
Fig. 3B). The pair-wise comparison, taking quartile I as
eferent, was similar for quartile II (p 0.78), but the event
ate was significantly greater in quartile III (p  0.007) and
uartile IV (p  0.001). The HRs for MI for quartiles II,
Figure 2 Failure Rate by PRU Quartiles
Kaplan-Meier curve for probability of death, myocardial infarction (MI), or stent thro
the group with the lowest PRU values, was taken as referent. Pair-wise compariso
*Log-rank p values were adjusted for multiple comparisons.III, and IV compared to quartile I were 1.34 (95% CI: 0.78
to 2.30), 2.23 (95% CI: 1.36 to 3.64), and 2.93 (95% CI:
1.82 to 4.71), respectively.
The rate of stent thrombosis by PRU quartile is shown in
Figure 3C. The event rate was significantly greater in
quartile IV compared to quartile I, 3.4% versus 0.4%,
respectively (p  0.002). However, there was no significant
ifference between quartile II (p  0.67) and quartile III
p  0.59) compared to quartile I. The corresponding HRs
or quartiles II, III, and IV, taking quartile I as referent,
ere 3.26 (95% CI: 0.68 to 15.69), 3.11 (95% CI: 0.65 to
4.96), and 7.48 (95% CI: 1.72 to 32.52), respectively.
hreshold analysis. Using logistic regression, a receiver-
perating characteristic curve was able to distinguish be-
ween patients with and without subsequent ischemic events
AUC: 0.61; 95% CI: 0.57 to 0.65; p 0.001). The optimal
ut-off value to predict death, MI, or stent thrombosis was
PRU value of 230, with corresponding sensitivity, speci-
city, positive predictive value, and negative predictive
alues of 55%, 65%, 11%, and 95%, respectively. Patients
ith PRU values 230 were categorized as having high
n-treatment platelet reactivity, and patients with values
230 as having normal on-treatment platelet reactivity.
here were no differences in patients with or without high
n-treatment platelet reactivity for female sex (36% vs. 39%;
 0.11), hypertension (32% vs. 38%; p  0.22), dyslipi-
emia (37% vs. 37%; p  0.92), or an acute coronary
yndrome (36% vs. 38%; p  0.54). However, diabetes was
ignificantly more frequent among subjects with high on-
reatment platelet reactivity, 30% versus 21% (p  0.001).
is (ST) by P2Y12 reaction unit (PRU) quartiles at 2 years. Quartile 1,
e then made with the referent group and adjusted for multiple comparisons.mbos
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Platelet Reactivity and Clinical Outcomes November 1, 2011:1945–54The Kaplan-Meier curve for the composite primary
endpoint of death, MI, or stent thrombosis is shown in
Figure 4A. Patients with high on-treatment platelet reac-
tivity had a significantly higher event rate for the primary
endpoint, 14.7% versus 7.0% (p  0.001); the correspond-
ing HR for the high versus normal on-treatment platelet
reactivity was 2.10 (95% CI: 1.62 to 2.73; p  0.0001)
Table 2). When effects on individual endpoints were
xamined, a PRU value 230 was associated with a signif-
cantly higher rate of mortality (HR: 1.66; 95% CI: 1.03 to
.68; p  0.04), MI (HR: 2.04; 95% CI: 1.51 to 2.76; p 
.001), and stent thrombosis (HR: 3.11; 95% CI: 1.50 to
.46; p  0.002).
In sensitivity analyses, we divided the cohort into deriva-
ion and validation datasets. Using the derivation dataset,
he bootstrap (sampling with replacement) analysis com-
rising 100 iterations yielded a PRU threshold value similar
o the main analysis; the average best PRU cutoff was 231
95% CI: 190 to 272) (Online Table 1). In the derivation
ataset, the Kaplan-Meier failure rate among subjects above
Figure 4 Failure Rate for Normal and High On-Treatment
Platelet Reactivity
Kaplan-Meier curve for probability of death, MI, or ST by platelet reactivity. High
on-treatment platelet reactivity (blue lines) was defined as PRU values 230
and normal (red lines) as PRU values 230. Dashed lines  95% confidence
intervals for each group. (A) Full cohort. (B) Landmark analysis starting day 4
after percutaneous coronary intervention. Abbreviations as in Figure 2.Figure 3 Failure Rate for Components of
the Primary Endpoint by Quartiles
Kaplan-Meier curve for probability of (A) death, (B) MI, and (C) ST by PRU quartiles
(Q). Quartile 1 (red lines) was taken as referent; green lines  Q2, blue lines  Q3,
orange lines  Q4. *Log-rank p values were adjusted for multiple comparisons.
Abbreviations as in Figure 2.he 231 threshold was 14.1% compared to 7.1% among
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November 1, 2011:1945–54 Platelet Reactivity and Clinical Outcomessubjects below the cutoff (p  0.0001); the corresponding
HR was 2.07 (95% CI: 1.50 to 2.86; p  0.001) (Online
ig. 2). The performance of the PRU threshold was then
valuated in the validation dataset. The Kaplan-Meier
ailure estimate for the event rate remained qualitatively
nchanged; it was 14.8% for patients above the threshold
nd 7.3% for patients below the threshold (p 0.0002); the
R was 2.00 (95% CI: 1.38 to 2.91; p  0.001) (Online
ig. 3).
The net discrimination improvement was also deter-
ined for the PRU threshold value of 230 as well as PRU
uartiles. The net discrimination improvement was 0.23 in
oth analyses (p 0.001). The IDI was also similar for both
RU variables; in both analyses, the IDI was 0.01 (p 
.001). Reclassification tables are provided in the Online
ppendix.
ubgroup analysis. The event rates for pre-specified sub-
roups of sex, age, diabetes, and clinical presentation were
lso determined (Table 3). High on-treatment platelet
eactivity was associated with higher rates of death, MI, or
tent thrombosis for men and women, for patients ages65
ears or65 years, and for persons with or without an acute
oronary syndrome presentation. However, for diabetes,
ssessment of platelet reactivity was associated with a
ignificantly higher event rate in the cohort without diabetes
nly. The HR for subjects with high versus normal on-
reatment platelet reactivity was 2.49 (95% CI: 1.84 to 3.39;
 0.0001) for nondiabetic patients and 1.30 (95% CI: 0.79
o 2.15; p  0.32) for diabetic patients (pinteraction  0.03).
In post-hoc analyses, we investigated the relationship
etween type of stent and adverse cardiovascular outcomes.
or the composite primary endpoint of death, MI, or stent
hrombosis, the HR for high versus normal on-treatment
eactivity for patients treated with bare metal stents or
rug-eluting stents was 2.49 (95% CI: 1.44 to 4.32; p 
.001) and 2.27 (95% CI: 1.57 to 3.03; p  0.001),
espectively.
ensitivity and influence analysis. Because peri-procedural
I was included in certain studies, we performed a sensitivity
nalysis where all events in the first 3 days after PCI were
ensored. In this 3-day landmark analysis, the results were
ualitatively similar to those in the main analysis. The rate of
he composite primary endpoint was significantly greater in the
igh on-treatment platelet reactivity group, 12.7% versus 6.2%,
espectively (p 0.001) (Fig. 4B). The corresponding HR was
.98 (95% CI: 1.48 to 2.65), for the composite primary
ndpoint (p  0.0001). For the components of the primary
ndpoint, the HR in the landmark analysis was 1.68 (95% CI:
.04 to 2.71; p  0.03) for death, 1.86 (95% CI: 1.31 to 2.63;
 0.0004) for MI, and 2.80 (95% CI: 1.41 to 5.56; p 
.003) for stent thrombosis.
In influence analysis, we investigated the impact of the
argest study in the cohort. When the study by Breet et al.
12), which enrolled 1,069 patients, was removed from the
nalysis, the primary results were unchanged. The HR for
he primary endpoint, taking quartile I as referent, was 1.03 r95% CI: 0.59 to 1.82; p  0.92) for quartile II, 1.75 (95%
I: 1.04 to 2.95; p  0.035) for quartile III, and 2.15 (95%
I: 1.31 to 3.52; p  0.003) for quartile IV. For patients
ith a PRU value 230 versus 230, the results were also
similar to the main analysis; the HR for death, MI, or stent
thrombosis for PRU 230 versus 230 was 1.83 (95% CI:
.27 to 2.62; p  0.001).
iscussion
e performed a patient-level pooled meta-analysis of 6 pro-
pective studies that quantified on-clopidogrel platelet reactiv-
ty with a uniform methodology in patients undergoing PCI.
he principal finding of our study is that higher on-treatment
latelet reactivity measured using the VerifyNow P2Y12 assay
as predictive of long-term ischemic events.
ain outcomes. We observed a higher event rate of the
omposite primary endpoint of death, MI, or stent throm-
osis for increasing levels of on-treatment platelet reactivity
hrough 2 years of follow-up. Importantly, the highest
uartile of PRU values (i.e., highest level of on-treatment
latelet reactivity), was also associated with a significant increase in
he individual rates of nonfatal MI and stent thrombosis.
he event rate for the primary endpoint in the highest
uartile of PRU values was significantly greater compared to
he lowest quartile, 15.8% versus 5.8% (HR: 2.62; 95% CI:
.77 to 3.87; p  0.001). Quartile III was also associated
ith a higher rate of death, MI, and stent thrombosis when
ompared to quartile I (p  0.005). For the primary or
econdary endpoints, there were no significant differences
etween quartiles I and II. Therefore, our observations
upport a threshold effect for the relationship between
n-treatment reactivity and ischemic events after PCI. We
dentified a potential cut-off value of a PRU 230 for high
n-treatment platelet reactivity and the composite endpoint
f death, MI, or stent thrombosis after PCI using receiver-
perator characteristics curve analysis.
tent thrombosis. Stent thrombosis remains a vexing
roblem associated with a high rate of morbidity and
ortality after PCI. In both the quartile and threshold
nalysis using the 230 PRU cut-off, we observed a signifi-
antly higher rate of stent thrombosis in persons with higher
n-treatment platelet reactivity. The stent thrombosis rate
sing the threshold value of 230 PRU was 3.0% vs. 1.0%;
he corresponding HR was 3.11 (95% CI: 1.50 to 6.46; p 
.002). A similar observation was made in a smaller cohort
tudy using ADP mediated platelet aggregation. In that
tudy, non-responsiveness to clopidogrel was associated
ith a HR of 3.08 (95% CI: 1.32 to 7.16; p  0. 009) for
tent thrombosis (18). The ability of a single antiplatelet
ggregation assessment after PCI to predict stent thrombo-
is may have important clinical implications.
ensitivity analyses and subgroups. We performed a
andmark analysis in an attempt to better understand the
mportance of platelet P2Y12 reactivity testing after PCI with
espect to longer-term outcomes. There remained a significant
c
f
n
0
A
s are K
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term out-of-hospital ischemic events when events during the
first 3-days after PCI were excluded. This observation further
supports the relationship between high on-treatment platelet
reactivity identified around the time of PCI and the risk of
long-term adverse cardiovascular events.
We performed several pre-specified subgroup analyses to
determine whether the effect of high on-treatment reactivity
was consistent across the population studied. We observed
similar rates of the composite of death, MI, or stent
thrombosis for subjects65 or65 years of age, for women
and men, for the presence of or absence of an acute coronary
syndrome presentation, and for patients treated with drug-
eluting or bare metal stents. Interestingly, we observed a
potential interaction in the diabetic subgroup. Quantifying
platelet reactivity after PCI appeared significantly predictive
in patients without diabetes but did not reach statistical
significance in patients with diabetes. That raises the ques-
tions of whether risk stratification with platelet function
testing may be especially important for patients without
diabetes; this potential interaction warrants further investi-
gation in future studies.
Threshold analyses. The threshold PRU value of 230,
obtained using the full cohort, is associated with an increase in
death, MI, and stent thrombosis after PCI. To assess the
robustness of this value, the full cohort was divided into
derivation and validation datasets. The PRU threshold from
this analysis, 231, was qualitatively similar to the 230 cutoff.
Event Rates According to On-Treatment PlateleTable 2 Event Rates According to On-Treatm
On-Treatme
Platelet Reactivity
PRU >230
Death/MI/stent thrombosis 124/1,133 (14.7)
Death 33/1,133 (4.5)
MI 92/1,133 (10.3)
Stent thrombosis 26/825 (3.8)
*n  number of events; N  number of subjects per group; %  rate
MI  myocardial infarction; PRU  P2Y12 reaction units.
Selected Subgroup Analysis by On-Treatment Platelet Reactivity StTable 3 Selected Subgroup Analysis by On-Treatment Platelet
On-Treatment
Platelet Reactivity, n/N (%)*
Death/MI/Stent Thrombosis
High
(PRU >230)
Normal
(PRU <23
Male 87/748 (16.2) 70/1,324 (7.
Female 37/385 (12.1) 33/601 (6.
Age 65 yrs 77/697 (14.6) 64/1,022 (8.
Age 65 yrs 47/436 (14.7) 39/904 (5.
Diabetes, yes 32/346 (13.1) 29/401 (10
Diabetes, no 92/787 (15.3) 74/1,522 (6.
Acute coronary syndrome, yes 16/144 (11.1) 11/256 (4.
Acute coronary syndrome, no 92/743 (12.4) 64/1,232 (5.
*n  number of events; N  number of subjects per group; %  rates are Kaplan-Meier estimate
subgroup interaction estimates.
Abbreviations as in Table 2.The composite primary outcome was validated internally using
the derivation dataset by sampling with replacement for 100
iterations. External validation was performed using the valida-
tion cohort. Kaplan-Meier failure rates and corresponding
HRs were similar in the derivation and validation cohorts,
supporting the PRU threshold identified.
Despite the statistical significance and consistency of
these findings, the AUC or c-statistic of the assay used was
modest. The AUC in the component studies ranged from
0.61 to 0.80, and in the pooled analysis, it was 0.61.
Receiver-operating characteristic curve analysis is frequently
used to describe diagnostic test performance, with the AUC
being indicative of the discriminatory ability of the test in
question compared to a gold standard (19). Whereas diag-
nostic tests used to identify patients with a specific disease
often have high AUCs, tests used to identify patients at risk
of having a clinical endpoint (like that examined in the
present study) often have modest AUCs. Prognostication
frequently involves estimating risk or the probability of a
future event, adding a stochastic element, distinguishing
this task from diagnosis (20). Methods are not well devel-
oped for time to event data; therefore, AUC values from
predictive models should be interpreted cautiously (21). For
omparison, in a comprehensive assessment by the Agency
or Health Care Quality and Research the AUC for B-type
atriuretic peptide (BNP) and NT-proBNP were 0.57 to
.88 across several studies, not notably different from the
UC range observed using the VerifyNow P2Y12 assay in
ctivity StatusPlatelet Reactivity Status
(%)* Hazard Ratio
<230 95% Confidence Interval p Value
,908 (7.0) 2.10 (1.62–2.73) 0.0001
,908 (2.5) 1.66 (1.03–2.68) 0.04
,908 (5.2) 2.04 (1.51–2.76) 0.0001
,087 (1.5) 3.11 (1.50–6.46) 0.002
aplan-Meier estimates.
tivity Status
Hazard Ratio
(95% Confidence Interval) p Value† p Value‡
2.37 (1.73–3.24) 0.0001 0.27
1.73 (1.08–2.78) 0.02
1.84 (1.32–2.56) 0.0003 0.20
2.56 (1.69–4.00) 0.0001
1.30 (0.79–2.15) 0.32 0.03
2.49 (1.84–3.39) 0.0001
2.97 (1.37–6.45) 0.006 0.64
2.47 (1.79–3.40) 0.0001
p value is for treatment comparisons within the subgroup. ‡The p value is testing the treatment t Reaent
nt
, n/N
PRU
103/1
34/1
78/1
14/1atusReac
0)
1)
4)
4)
5)
.9)
2)
3)
2)
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mous separation, there remains a strong relationship be-
tween PRU values on the continuous scale and the primary
endpoint. The rate of death, MI, or stent thrombosis
increased by 4% for every 10-U increase in PRU (p 
0.0001); and there was a strong association observed using
the 230 PRU cut-off with the “hard” clinical endpoints of
death, nonfatal MI, and stent thrombosis, with an absolute
risk difference of 7.7%. Also, both IDI and NRI support
quantifying platelet reactivity; NRI improved classification
for a net of 23% of subjects.
Future directions. Several antiplatelet strategies may po-
entially be used in patients with high on-treatment platelet
eactivity (23–26). The GRAVITAS (Gauging Responsive-
ess With A VerifyNow Assay–Impact on Thrombosis and
afety) trial showed that increasing the clopidogrel mainte-
ance dose from 75 mg to 150 mg daily did not lower
schemic events among low-risk subjects with high-on
reatment platelet reactivity; interestingly, bleeding events
ere also similar between groups (27). The event rate of
.3% in both groups was considerably lower than predicted
5%); therefore, the trial was underpowered for the com-
osite primary endpoint of death, MI, or stent thrombosis.
n aggregate, these observations suggest very low risk
atients were enrolled. Because stable patients after PCI
ere included in the GRAVITAS study, the event rates
rom our landmark analysis provide insight into the antici-
ated event rates. In the landmark analysis, the event rates
t 180 days in the normal and high on-treatment platelet
eactivity groups were 2.5% and 3.8%, respectively; this
nding suggests the expected event rate of 5% and antici-
ated 50% relative risk reduction in the GRAVITAS trial
as somewhat optimistic. A lower than expected event rate
as also lead to the termination of the TRIGGER–PCI
Testing Platelet Reactivity in Patients Undergoing Elective
tent Placement on Clopidogrel to Guide Alternative Ther-
py With Prasugrel) trial. In the present study, the greatest
eparation of the Kaplan-Meier curve was observed beyond
80 days; before 180 days, there was considerable overlap in
he 95% CIs. These observations suggest that future trials
ill need to recruit larger cohorts, extend follow-up, or
oth. In summary, additional intervention trials are required
o better understand how platelet function testing can be
ntegrated into the treatment of patients undergoing PCI,
ncluding in the acute coronary syndrome setting where
rasugrel is indicated. In the absence of such data, recom-
endations for routine testing are not possible.
tudy limitations. In the present study, data regarding
CYP2C19 genotype were not available; therefore, the impact
of genotype on platelet function and clinical outcomes could
not be assessed. Also, we were not able to assess bleeding
complications because this outcome was not consistently
included in the trials we included in our analysis. Bleeding
complications are very important with respect to mortality
risk; however, their clinical importance in relation to oralantiplatelet therapy has been recognized after completion of
the studies we analyzed (28).
Conclusions
The results of this study show that high on-treatment platelet
reactivity around the time of PCI is associated with long-term
cardiovascular events including death, MI, and stent thrombo-
sis. These findings were consistently observed in landmark,
sensitivity, and influence analyses. Also, using the P2Y12
point-of-care assay, a PRU value of 230 was associated with
igher rates of death, MI, or stent thrombosis. Future ran-
omized controlled trials investigating the role of oral anti-
latelet therapy guided by P2Y12 reactivity testing will provide
insights into effective therapeutic interventions for patients
with high on-treatment platelet reactivity.
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